Axel N.
- Country
- Sweden
- Department
- Allmänpsykiatrin, Universitetssjukhuset Örebro, Region Örebro län
Research Overview
- Long-Term Safety and Efficacy of Repeated Rituximab as Adjunctive Therapy in Patients with Schizophrenia Spectrum Disorders (RITS‑LONG)
- Optimized pharmacological treatment for broken heart (takotsubo) syndrome
- Evaluation of Psilocybine for Major Depressive Disorder in Cancer Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 8 of 23 partner sites.
Specializations
Psychiatric Treatment Innovation
This investigator specializes in treating major depressive disorder (MDD), exploring innovative therapeutic approaches including both traditional and emerging treatment modalities.
- Electroconvulsive Therapy Optimization
- Psychedelic-Assisted Treatment
- Treatment-Resistant Depression
Key focus on advancing anesthetic protocols in electroconvulsive therapy to enhance treatment outcomes.
Oncology-Related Mental Health
The investigator addresses the complex intersection of cancer-related depression and mental health, particularly focusing on novel therapeutic interventions.
- Cancer-Associated Depression
- Psycho-oncology
- Integrated Cancer Care
Expertise in managing psychological complications in patients with malignant tumors.
Alternative Treatment Methods
Investigates the therapeutic potential of psilocybin in treating depression, particularly in specialized patient populations.
- Single-Dose Interventions
- Novel Antidepressant Approaches
- Therapeutic Drug Applications
Focus on developing alternative treatments for patients requiring specialized mental health interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.